Pharmacokinetic Analysis of an Isoniazid Suspension Among Spanish Children Under 6 Years of Age
<b>Background</b>: Isoniazid (INH) remains a first-line drug for the treatment of tuberculosis (TB) in young children. In 2010, the WHO recommended an increase in the daily dose of INH up to 10 (7–15) mg/kg. Currently, there are no INH suspensions available in Europe. <b>Methods<...
Saved in:
Main Authors: | Antoni Noguera-Julian, Emma Wilhelmi, Maria Cussó, Rob Aarnoutse, Angela Colbers, Loreto Martorell, Maria Goretti López-Ramos, Joan Vinent, Rosa Farré, Dolors Soy, Sílvia Simó-Nebot, Clàudia Fortuny |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-01-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/14/1/74 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The role of isoniazid dosage and NAT2 gene polymorphism in the treatment of tuberculous meningitis
by: Yi Jian, et al.
Published: (2025-01-01) -
Hepatoprotective potential of Chrysin in a rat model of isoniazid- and rifampicin-induced hepatic injury: suppression of matrix metalloproteinase and transforming growth factor β
by: Deepa Mandlik, et al.
Published: (2025-01-01) -
Alcohol use and HIV suppression after completion of financial incentives for alcohol abstinence and isoniazid adherence: a randomized controlled trialResearch in context
by: Winnie R. Muyindike, et al.
Published: (2025-02-01) -
Early bactericidal activity of sitafloxacin against pulmonary tuberculosis
by: Lihui Nie, et al.
Published: (2025-01-01) -
Tuberculosis preventive treatment in newborns
by: Tony TannousTahan, et al.
Published: (2025-01-01)